Welcome to our dedicated page for NewcelX news (Ticker: NCEL), a resource for investors and traders seeking the latest updates and insights on NewcelX stock.
NewcelX Ltd. (Nasdaq: NCEL) is a Zurich-based clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The NewcelX news feed on Stock Titan highlights company announcements that shed light on its ALS, Type 1 Diabetes, and CNS-focused programs, as well as its broader strategy in regenerative medicine and neuroscience.
Investors and observers can follow updates on AstroRx®, NewcelX’s cell-therapy program for ALS, and IsletRx, its stem-cell–derived islet therapy for insulin-dependent Type 1 Diabetes. News items include results from international collaborative studies on biomaterial approaches for stem-cell–derived islet delivery, which explore engineered scaffolds and extracellular matrix integration to support islet function and potentially reduce the need for chronic immunosuppression.
The news stream also covers developments in the DOXA small-molecule platform, such as publication of patent applications in key markets like China for quinazoline, benzothiazine, and benzoxazine derivatives targeting neurological diseases. These updates provide insight into how NewcelX is expanding its intellectual property footprint and advancing CNS drug discovery linked to sleep-wake regulation, orexin signaling, and metabolic control.
Additional coverage features scientific and strategic appointments to the company’s Scientific Advisory Board, reflecting expertise in diabetes innovation, ALS, neuroimmunology, and stem-cell-based regenerative medicine. Corporate communications, including shareholder letters and roadmap updates following the merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., offer context on NewcelX’s integrated platform, clinical plans, and financial positioning. For readers tracking NCEL, this news page brings together scientific, clinical, intellectual property, and governance milestones in one place.
NewcelX (Nasdaq: NCEL) announced a private placement priced at $2.75 per share, a 30% premium to the March 31, 2026 close, selling 490,907 common shares and warrants to purchase 687,270 shares at a $3.025 exercise price.
Proceeds, together with a previously announced $25 million equity line, are intended to advance NCEL-101 for Type 1 Diabetes, other pipeline programs, working capital and general corporate purposes; closing is expected on or about April 15, 2026 subject to customary conditions.
NewcelX (Nasdaq: NCEL) announced a collaborative research agreement with Eledon Pharmaceuticals (Nasdaq: ELDN) to evaluate combination strategies pairing NewcelX's lead stem-cell-derived islet program, NCEL-101, with Eledon's anti-CD40L antibody tegoprubart (AT-1501).
The collaboration leverages clinical experience from >100 transplant patients treated with tegoprubart and aims to support durable, immune-protected islet replacement, potentially clarifying regulatory pathways and accelerating NCEL-101 development toward pivotal milestones.
NewcelX (Nasdaq: NCEL) announced a peer-reviewed publication on Mazindol IR/SR in Clinical Drug Investigation, strengthening the scientific case for Mazindol ER under its CVR framework. The paper is cited via DOI and is said to bolster licensing and acquisition negotiations to maximize CVR value realization.
Management reports advanced, structured discussions with multiple counterparties and highlights IP dating to 2006 and over 20 years of research supporting CNS indications including narcolepsy, ADHD, and substance use disorders.
NewcelX (NASDAQ: NCEL) released an updated corporate presentation on Jan 29, 2026, ahead of spring 2026 investor and partnering conferences, including BIO-Europe Spring in Lisbon. The deck emphasizes a sharpened strategic focus on Type 1 Diabetes cell therapy, recent scientific progress, clinical priorities, and new Scientific Advisory Board and leadership appointments to support near- and mid-term value-creation milestones.
Management will be available for one-on-one meetings at upcoming conferences and the presentation is available on the company website.
NewcelX (Nasdaq: NCEL) reported positive results from an international collaborative study published Jan 12, 2026 in Diabetology testing engineered scaffolds that incorporate decellularized human pancreatic extracellular matrix (ECM) to support delivery of stem cell–derived islets for Type 1 Diabetes.
The study found that ECM‑integrated scaffolds yielded implanted islet functional performance comparable to encapsulated islets delivered without a scaffold, and highlighted biomaterial design and tissue microenvironment as key to enabling retrievable, immune‑sparing delivery approaches. Funding came from AFDR, the National Stem Cell Foundation of Australia, and Breakthrough T1D.
NewcelX (NASDAQ: NCEL) appointed Dr. Julien Boisdron to its Scientific Advisory Board on January 5, 2026. Dr. Boisdron is described as a diabetes expert with more than two decades of global leadership and currently serves as Chief Medical Officer at a major Swiss-based multinational pharma company.
He will advise on strategic development of IsletRx, NewcelX's lead stem-cell-derived islet cell therapy for insulin-dependent Type 1 Diabetes, focusing on translational strategy, patient adoption, health-system integration, and future commercialization as the program advances toward clinical trials.
NewcelX (Nasdaq: NCEL) announced publication in China of an international patent application covering a new class of DOXA quinazoline, benzothiazine, and benzoxazine derivatives for neurological diseases (China publication CN 120981232 A, published November 18, 2025).
The portfolio expansion builds on a Europe priority filing (priority Dec 30, 2022) and a PCT filing (Dec 29, 2023), and the company says the DOXA family targets sleep‑wake regulation, neuroinflammation, oxidative stress, and neuronal resilience with potential applications across narcolepsy, ALS, neurodegeneration, and metabolic disease.
The publication supports NewcelX's small‑molecule IP footprint in Asia, mentions potential Hong Kong registration, and links DOXA mechanisms to the company's stem‑cell IsletRx work for insulin‑dependent diabetes.
NewcelX (Nasdaq: NCEL) announced on November 17, 2025 the appointment of Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board.
Prof. Shefner is Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute and is an ALS and neuromuscular disorder specialist with more than 200 peer-reviewed papers and co‑founder status of the Northeast ALS Clinical Trials Consortium (NEALS).
He will advise on NewcelX's ALS programs, including clinical development of AstroRx, and support integration of neuromuscular and neurodegenerative expertise into the company's cell‑therapy and neuroscience platform.
NewcelX (NASDAQ: NCEL) announced on November 6, 2025 that Professor Tamir Ben-Hur, MD, PhD, will join its Scientific Advisory Board.
Prof. Ben-Hur is a professor of neurology at Hadassah and Hebrew University, described as an expert in neuroimmunology and stem-cell regenerative medicine. Management said his appointment brings clinical expertise to NewcelX's programs targeting ALS and diabetes. The company framed his commitment as an endorsement of the Merger that unites Kadimastem's stem-cell platforms with NLS Pharmaceutic's CNS therapeutics capabilities.
NewcelX (Nasdaq: NCEL) issued a letter outlining a unified strategy combining cell therapies and neuroscience programs and setting multiple near-term clinical and corporate milestones over the next 12 months.
Key items include a planned U.S. Phase 2a study of AstroRx for ALS, preparation for a U.S. Phase 1 trial of IsletRx (iTOL-102), DOXA program progression toward lead selection, and platform expansion into indications such as MS and glaucoma. The merger that formed NewcelX raised approximately $9 million and the company cites a $25 million equity line of credit, with pro forma shareholders' equity of about $20 million as of June 30, 2025.